You are here
Trametes versicolor in Women with Breast Cancer
This is a Phase II randomized-placebo controlled trial of a mushroom extract (Trametes versicolor or Tv) in women with early-stage estrogen receptor-negative and progesterone receptor-negative breast cancer who have completed adjuvant radiation therapy. The primary study endpoint is immune recovery as measured by changes in natural killer cell activity. The secondary endpoints include phagocytic activity, cytokine levels (TNF-alpha and interferon-gamma), and self-reported quality of life/fatigue scores using previously validated instruments. This data will help the investigators to determine if Tv extract has promise as an immune therapy, and/or whether it might be helpful to fight fatigue in women after they finish conventional breast cancer treatment.